Corrigendum to “Imatinib: A Breakthrough of Targeted Therapy in Cancer”

Chemotherapy research and practice Pub Date : 2020-12-28 DOI:10.1155/2020/1375374

N. Iqbal, N. Iqbal

引用次数: 2

Abstract

(iv) S. Verstovsek, “New Hematological Indications for Imatinib,”Hematological Cancer, 2007, doi: http://doi. org/10.17925/OHR.2007.00.2.36 (https://www.toucho ncology.com/articles/new-hematological-indicationsimatinib) [5] (not cited). (v) M. Breccia and G. Alimena, “Resistance to Imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem,” Cardiovascular and Hematological Disorders-Drug Targets, 2009, doi: https://doi.org/ 10.2174/187152909787581363 (http://www.eurekaselect. com/68887/article) [6] (not cited).

查看原文本刊更多论文

“伊马替尼:癌症靶向治疗的突破”的勘误表

(iv) S. Verstovsek，“伊马替尼的新血液学适应症”，血液学癌症，2007,doi: http://doi。http://www.10.17925/ohr.2007.00.2.36 (https://www.toucho ncology.com/articles/new-hematological-indicationsimatinib)[5](未引用)。(5)陈晓明，李晓明，“慢性髓系白血病患者对伊马替尼耐药性的研究进展”，中华心血管病杂志，2009,doi: https://doi.org/ 10.2174/187152909787581363 (http://www.eurekaselect)。http://www.68887 /article)[6](未引用)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemotherapy research and practice

自引率

0.00%

发文量